This summit will provide an opportunity for a varied group of stakeholders including providers, payers, patients, patient advocacy organizations, and industry, to thoughtfully discuss patient access to high-quality, effective, and efficient oncology care, as well as to disseminate advances in oncology patient safety systems best practices, processes, and policies. The summit will also explore shifting health care priorities under the Trump Administration and any implications for safety and access to high quality cancer care.

**Agenda**

- **Safety and Accountability in Oncology Care**
- **Patient Access to Safe, High Quality Cancer Care Under a New Administration**
- **Panel Discussions:**
  - Safety and Accountability in Cancer Care: Past, Present, and Future
  - Barriers and Opportunities in Ensuring Access to Safe, High Quality Cancer Care

* Agenda subject to change

---

**Supporters**

Supported by Adaptive Biotechnologies; AmerisourceBergen; Apobiologix, a division of ApoPharma USA, Inc.; EMD Serono; Gilead Sciences, Inc.; HELSINN; Incyte Corporation; Janssen Oncology; Kite Pharma; National Decision Support Company; and Pharmacyclics LLC, An AbbVie Company. Sponsored by AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Biomedical, Inc.; and Dendreon. This activity is supported by a contribution from Lilly. Supported by an independent educational grant from Merck & Co., Inc. Supported by an unrestricted sponsorship from TESARO. (As of April 11, 2017)